Home Services Immuno-Oncology Suppression Assays

Suppression Assays

At Aquila, we offer a suite of assays for screening molecules or biologics for their ability to reverse suppression of T cells mediated by different immune cell populations such as M2 macrophages, MDSC and Tregs, an important mechanism of action (MOA) for any potential immunotherapy cancer treatment.

Macrophage Suppression Assay

The tumour microenvironment (TME) can drive differentiation and accumulation of immune cells, which support tumour growth e.g. tumour associated macrophages (TAMs) and M2 macrophages. Aquila have a range of customisable assays to screen compounds for their potential to block these mechanisms, reducing the suppression of T cells and boosting anti-tumour responses. Reversal of T cell suppression can be measured by cytokine release (ELISA, multiplex or MSD), gene expression changes (qPCR) or by proliferation and activation markers using flow cytometry.

We are developing ex vivo protocols, utilising tumour conditioned media (tumour cell lines and ascites samples) as well isolating TAMs, for use in our macrophage suppression assays as a translational step-up in complexity from our customisable in vitro assay systems.

MDSC Suppression Assay

Myeloid-derived suppressor cells (MDSC) are key players in the TME. Our MDSC-mediated T cell suppression assay can help you determine if your compound or biologic can block MDSC function and relieve T cell activation.

Treg Suppression Assays

Regulatory T cells (Tregs) can inhibit unwanted immunity e.g. in autoimmune diseases, or conversely, they can suppress desirable immunity in cancer. We have a customisable Treg suppression assay to study your drug candidate’s ability to either boost or reduce Treg activity. We work closely with you to tailor key assay readouts to your requirements.

Our Treg suppression assays can incorporate in vitro generated inducible FoxP3+ Tregs (iTregs) or natural Tregs (nTregs) can be isolated for use in this assay, more closely reflecting the FoxP3-induction potentially driven by some tumour types and highly relevant to immuno-oncology research.

Please get in touch to discuss your T cell suppression assay study requirements.

Contact